Additional nefopam reduces postoperative pain after primary total knee arthroplasty: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220814002

Enrollment

Registered

2022-08-14

Start date

2020-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee arthroplasty Pain Nefopam Total knee arthroplasty Pain Nefopam

Interventions

80 mg of nefopam in a normal saline (NSS) 500 ml continuously via intravenous drip in 24 hours for a total duration of 48 hours,Normal saline

Active Comparator Drug,Placebo Comparator Drug

Nefopam,Placebo

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1 Primary OA knee 2 Age between 50 to 85 years 3 Fully comprehension of Thai language

Exclusion criteria

Exclusion criteria: 1 Previous ipsilateral knee surgery 2 Contraindication to drugs used in the study (nefopam, ketorolac, parecoxib, paracetamol, tranexamic acid) 3 Chronic kidney disease which GFR <50 ml/min 4 Arrhythmic heart disease 5 Psychiatric disorder receiving serotonin or tramadol 6 Intraoperative fracture or ligamentous injury

Design outcomes

Primary

Measure	Time frame
Pain score at rest 6, 12, 18, 24, 36 and 48 hours postoperative Numerical rating scale score (NRS)	—

Secondary

Measure	Time frame
Morphine consumption 6, 12, 18, 24, 36 and 48 hours postoperative Mg	—

Countries

Thailand

Contacts

Public ContactSwist Chatmaitri

Siriraj Hospital

swist_swist@hotmail.com0819879990

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026